Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

The Beijing IP Court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and ...

Losing weight with Ozempic is an expensive undertaking because Novo Nordisk, the company that produces Ozempic, monopolizes ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic ...

Lars Jørgensen, chief executive of the Ozempic manufacturer Novo Nordisk, defended the prices of the company’s popular diabetes and weight loss medication in testimony to a Senate committee on ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing ...